Literature DB >> 25550888

PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.

Feifei Wen1, Shuang He2, Chenbo Sun1, Tangyue Li1, Shuhua Wu2.   

Abstract

The phosphoinositide 3-kinases (PI3Ks) are a critical family of signaling enzymes that participate in many cellular processes that promote the transformation of a normal cell into a cancer cell. These processes include cancer cell proliferation, migration, and invasion. However, the correlation between PI3Ks and multidrug resistance (MDR) remains unclear. The prognostic value of PI3Ks has not been previously evaluated. Thus, this study aims to evaluate the association between PIK3CA and PIK3CB expression and the MDR gene in colorectal cancer (CRC) patients. Immunohistochemistry was employed to detect the expressions of PIK3CA, PIK3CB, MDR-1, LRP, GST-π, and Topo II in 316 CRC specimens. Patients were followed-up annually by telephone or at an outpatient clinic. Results revealed that PIK3CA and PIK3CB expression was correlated with the degree of tumor differentiation and lymph node metastasis (P < 0.05). The overexpression of MDR-1, LRP, Topo II, and GST-π was found to be 72.78%, 70.89%, 77.53%, and 76.58% of CRC, respectively. Correlation analysis showed that PIK3CA and PIK3CB expression exhibits a positive correlation with MDR-1, LRP, and GST-π with correlation coefficients of 0.288, 0.128, and 0.197, respectively (P < 0.05). Kaplan-Meier analysis revealed that the five-year survival rate of patients without lymph node metastasis, positive expression of PIK3CA and PIK3CB, and negative expression of GST-π and MDR-1 was higher than those with these characteristics. Multivariate analysis revealed that GST-π, MDR-1 expression, and lymph node metastasis could serve as independent predictive factors of overall survival. The expression of both PIK3CA and PIK3CB is increased and related to the development and progress of colorectal carcinoma and MDR. The combined detection of PIK3CA andPIK3CB is important for patients with colorectal carcinoma in prognosis and optimal therapy.

Entities:  

Keywords:  Colorectal cancer; MDR; PIK3CA; PIK3CB; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25550888      PMCID: PMC4270546     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway.

Authors:  Liang Bo Zhu; Jian Jiang; Xiao Ping Zhu; Tao Fang Wang; Xuan Yin Chen; Qin Feng Luo; Yong Shu; Zhi Li Liu; Shan Hu Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer.

Authors:  Binbin Cui; Ji Tao; Yanmei Yang
Journal:  Cell Biochem Biophys       Date:  2012-01       Impact factor: 2.194

Review 3.  Oncogenic PI3K and its role in cancer.

Authors:  Yardena Samuels; Kajsa Ericson
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

Review 4.  Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment.

Authors:  Salvador Rodriguez-Nieto; Boris Zhivotovsky
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

5.  Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.

Authors:  Ana S Guerreiro; Sarah Fattet; Barbara Fischer; Tarek Shalaby; Shaun P Jackson; Simone M Schoenwaelder; Michael A Grotzer; Olivier Delattre; Alexandre Arcaro
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines.

Authors:  Mahmoud Zaki El-Readi; Dalia Hamdan; Nawal Farrag; Assem El-Shazly; Michael Wink
Journal:  Eur J Pharmacol       Date:  2009-09-24       Impact factor: 4.432

Review 7.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

8.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

9.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Authors:  Neil E Torbett; Antonio Luna-Moran; Zachary A Knight; Andrew Houk; Mark Moasser; William Weiss; Kevan M Shokat; David Stokoe
Journal:  Biochem J       Date:  2008-10-01       Impact factor: 3.857

Review 10.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

View more
  15 in total

1.  Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.

Authors:  Xiaoxiao Wan; Xian Li; Junyan Yang; Wei Lv; Qiming Wang; Ying Chen; Yong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  CSN5 silencing inhibits invasion and arrests cell cycle progression in human colorectal cancer SW480 and LS174T cells in vitro.

Authors:  Gang Zhong; Huikai Li; Tao Shan; Nan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

4.  Expression of PHLPP2 correlates with clinicopathologic characteristics and prognosis in colorectal cancer.

Authors:  Shu-Hua Wu; Xiao-Yang Xu; Chen-Bo Sun; Fei-Fei Wen; Shuang He; Xiang-Qian Gao; Yuan-Hang Liu; Liu Liu
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

5.  PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.

Authors:  Shuhua Wu; Feifei Wen; Yangyang Li; Xiangqian Gao; Shuang He; Mengyao Liu; Xiangzhi Zhang; Dong Tian
Journal:  Tumour Biol       Date:  2016-01-08

6.  Expression of PI3Kp110α and PI3Kp110β in the colorectal conventional adenoma, serrated lesions and adenoma with canceration and their significance.

Authors:  Shuhua Wu; Tangyue Li; Qinghai Mu; Yangyang Li; Xiangqian Gao; Shuang He; Chenbo Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

7.  Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.

Authors:  Si-Hyong Jang; Kyung-Ju Kim; Mee-Hye Oh; Ji-Hye Lee; Hyun Ju Lee; Hyun Deuk Cho; Sun Wook Han; Myoung Won Son; Moon Soo Lee
Journal:  J Gastric Cancer       Date:  2016-06-24       Impact factor: 3.720

8.  PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.

Authors:  A-Jian Li; Hua-Guang Li; Er-Jiang Tang; Wei Wu; Ying Chen; Hui-Hong Jiang; Mou-Bin Lin; Lu Yin
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

9.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

10.  Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.

Authors:  Shu Yang; Wenshuai Li; Haimei Sun; Bo Wu; Fengqing Ji; Tingyi Sun; Huanhuan Chang; Ping Shen; Yaxi Wang; Deshan Zhou
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.